NCT06810895View on ClinicalTrials.gov

Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix

Enrolling by invitationOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2032

Conditions

Cervix CancerCadonilimabSmall Cell Neuroendocrine Carcinoma of the Cervix

Trial Locations (1)

430000

ongji Hospital, Tongji Medical College, Huazhong University of Science andTechnology, Wuhan

All Listed Sponsors

lead

Ding Ma

OTHER